Display Settings:

Format

Send to:

Choose Destination
    J Int Med Res. 2009 Nov-Dec;37(6):1961-71.

    Improved survival in patients with end-stage cancer treated with coenzyme Q(10) and other antioxidants: a pilot study.

    Source

    Arnakkegårds alle 50, Vipperoed, Denmark. nhj@dadlnet.dk

    Erratum in

    • J Int Med Res. 2010 Jan-Feb;38(1):293.

    Abstract

    This pilot study evaluated the survival of patients with end-stage cancer who received supplements of coenzyme Q(10) and a mixture of other antioxidants (e.g. vitamin C, selenium, folic acid and beta-carotene). During a period of 9 years, 41 patients who had end-stage cancer were included. Forty patients were followed until death and one patient was lost to follow-up and presumed dead. Primary cancers were located in the breast, brain, lungs, kidneys, pancreas, oesophagus, stomach, colon, prostate, ovaries and skin. The median predicted survival time was calculated from Kaplan-Meier curves for each patient at inclusion. Median predicted survival was 12 months (range 3 - 29 months), whereas median actual survival was 17 months (1 - 120 months), which is > 40% longer than the median predicted survival. Mean actual survival was 28.8 months versus 11.9 months for mean predicted survival. Ten patients (24%) survived for less time than predicted, whereas 31 (76%) survived for longer. Treatments were very well tolerated with few adverse effects.

    PMID:
    20146896
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Ingenta plc

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk